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CELLULAR AND INFECTION MICROBIOLOGY
The adult human intestine is home to an 
almost inconceivable number of microor-
ganisms. Their population is up to 100 tril-
lion, nearly 10 times larger than the total 
number of our somatic and germ cells. All 
three domains, including bacteria, archaea, 
and eukarya, are contained in the adult 
human gastrointestinal (GI) tract and the 
bacteria achieve the highest cell densities and 
phylogenetic diversities (Whitman et al., 
1998). Such gut microbiome can be viewed as 
a microbial organ placed within a host organ 
and the genomes of our affiliated microbial 
partners (the microbiome) may contain 
more than 100 times the number of genes 
in our genome. Once established, the indig-
enous microbiota provides many crucial 
functions to the host endows us with func-
tional features that we have not had to evolve 
ourselves (MacDonald and Monteleone, 
2005). These have been reviewed elsewhere 
(Ley et al., 2009; Neish, 2009) and include 
the contribution to digestion (such as the 
ability of microbes to break down host non-
digestible polysaccharides) and its second-
ary benefits (the generation of SCFA), the 
metabolism of xenobiotics, the development 
of human immune system, and the coloniza-
tion resistance. Generally, a healthy human 
state is a homeostasis between the micro-
biota and the host. Maladies such as Crohn’s 
disease, chronic periodontitis, and bacterial 
vaginosis are characterized by a disruption 
of this homeostasis, a state known as dys-
biosis (Tamboli et al., 2004). Meanwhile, the 
composition of the intestinal microbiota can 
undergo dynamic changes as a result of its 
interactions with diet, genotype/epigenetic 
composition, and immune-metabolic func-
tion (Kau et al., 2011). We envision a future 
in which new therapeutics and diagnostics 
enable the management of our microbiota to 
treat and prevent disease. Here, the relation-
ship between gut microbiome and diseases 
and the effort in adjusting the gut microbi-
ome will be discussed briefly.
use of probiotics, prebiotics, and synbiotics 
suggested the potential for controlling these 
diseases through manipulation of the com-
position of the gut microbiota, and direct 
interactions with the gut immune system 
(MacFarlane et al., 2009).
Obesity and type 2 diabetes (T2D), the 
most prevalent metabolic diseases world-
wide, are considered to be induced by 
impact of the microbiota on our metabolic 
health. Turnbaugh et al. (2009) observed 
that obesity is associated with phylum-level 
changes in the microbiota, reduced bacterial 
diversity, and altered representation of bac-
terial genes and metabolic pathways. The 
hypothesis is that the microbiota in obese 
individuals can harvest the more energy 
from food than the one in lean individuals. 
And another hypothesis is that gut micro-
biota can modulate plasma LPS levels which 
triggers chronic low-grade inflammation 
leading to obesity and diabetes (Cani et al., 
2007). Another disease that related with 
obese tightly is non-alcoholic fatty liver. 
The intestinal microbiota may contribute 
to the development of non-alcoholic fatty 
liver disease through the complex and coop-
erative activities of two microbe-sensing 
protein families, namely nucleotide oli-
gomerization domain receptors (NLRs) and 
Toll-like receptors (TLRs; Mukhopadhyay 
et al., 2011; Yeretssian, 2012), and through 
inflammasomes (Henao-Mejia et al., 2012) 
that shape metabolic pathway such as lipid 
accumulation.
The gut microbiota has a considerable 
impact on the host’s intestinal immunity 
and immune responses. Rheumatoid 
Arthritis (RA), a systemic autoimmune 
disease, is considered to be linked with gut 
microbiome. The antibodies to P. gingivalis 
have been reported to be more frequent in 
RA subjects compared with controls and 
that the titer of RA-related autoantibod-
ies and C-reactive protein concentrations 
are also higher in individuals infected with 
The human GuT microbioTa and 
diseases
The human gut harbors diverse microbes 
that play a fundamental role in the health 
of their host. It differs from person to per-
son depending on the unique species of 
bacteria accumulated over a lifetime. This 
means that every person’s health is dis-
tinctly influenced by the specific byprod-
ucts created by their particular microbiota 
(Goodacre, 2007). Microbiome, considered 
as our “forgotten organ,” has been studied 
by some large-scale international projects 
such as HMP (Turnbaugh et al., 2007; 
Peterson et al., 2009) and MetaHIT (Qin 
et al., 2010). Based on an increasing number 
of studies on human microbiome, includ-
ing the microbial community structure and 
function (Huttenhower et al., 2012), the 
researchers are shifting their concerns to the 
role of human microbiota in development 
of some acute or chronic diseases, especially 
GI Disorder. And the understanding that 
pathogenesis of some diseases is associated 
with result of complex interactions between 
microbiota and host was accepted more and 
more commonly.
The most frequently reported disease 
that has been proved to associate with 
dramatic changes in the gut microbiota 
is Inflammatory Bowel Disease (IBD; 
Dicksved et al., 2008). MacFarlane et al. 
(2009) revealed significant reductions 
in Bifidobacterium populations in rectal 
biopsies from IBD patients. Zhang et al. 
(2007) have shown that bacterial diver-
sity of Lactobacilli varied greatly between 
ulcerated tissue and non-ulcerated tissue in 
the same UC individuals. The number of 
mucosal adherent bacteria, such as invasive 
E. coli, Proteobacteria, Enterobacteriaceae are 
increased in IBD patients’ gut (Nagalingam 
and Lynch, 2012). Despite the involvement of 
microorganisms in inflammatory processes, 
antibiotic therapy was unsuccessful in IBD. 
However, recent studies  demonstrated the 
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the complex gut composition and its influ-
ence on human health. Several challenges 
remain to be overcome in a near future. 
Firstly, the list of the diseases that related 
to the gut microbiome is just growing and 
growing, and these diseases are usually 
complex in terms of both pathogenesis 
and complication, while sequencing and 
computational technologies would be a 
bottleneck in large-scale correlation analysis 
between the human microbiome and dis-
eases. Secondly, despite a growing number 
of researches discovered the relationship 
between alterations in the gut microbiome 
and diseases, it remains to be established 
whether these are causes or effects. Further 
studies are required to distinguish disease-
associated changes from a mass of inter-
individual variations that observed in the 
microbiome. Thirdly, time-series studies of 
individuals to monitor the status alter pro-
cess from health to disease and back to the 
health is necessary for exploring the change-
able human microbiome. High-resolution 
time-series studies provide a feasibility to 
discriminate between “normal” perturba-
tions and pathologic states, and between 
organisms that are simply passing through 
a body habitat and are entrenched resi-
dents of an ecosystem (Eckburg et al., 2005; 
Palmer et al., 2007; Koenig et al., 2011). In 
some studies, (Huse et al., 2008; Dethlefsen 
and Relman, 2010) rapid decreases in alpha 
diversity and a characteristic shift in com-
munity composition were observed in 
association with antibiotic therapy, fol-
lowed by a rapid post-antibiotic increase 
in diversity as the gut community returned 
to a state similar (but not identical) to the 
pre-treatment state. Furthermore, despite 
a large number of reports have showed the 
different gut microbiome between patient 
and healthy person, the definition of “the 
healthy gut microbiome” remains unclear. 
And the methodologies that can change the 
unhealthy gut microbiome to a healthy one 
are still in investigation.
In terms of its application of human 
gut microbiome for human health devel-
opment, we propose to monitor the micro-
biome when being healthy, and to establish 
a baseline indicating healthy, with more 
intensive monitoring when being sick and 
during treatment period. Such method 
demands the development of new diag-
nostic tools that are both accurate and suf-
ficiently rapid to inform decisions regarding 
microbiome. Modern medicine is struggling 
to seek methods of treating these multi-
component diseases. The ancient medical 
philosophies and practices of Asia – particu-
larly those of traditional Chinese medicine 
(TCM) – can offer an alternative approach. 
TCM’s reliance on complex mixtures of 
compounds and its philosophy – complete 
system needs to be balanced – of treating 
the human body, match up well with the 
synergistic properties of the gut microbi-
ome (Crow, 2011). In addition, most herbal 
medicines are orally administered, which 
will result in the unavoidable exposure of 
these medicines to the microorganisms in 
the gut. During this process, some of them 
are selectively metabolized into active or 
absorbable components by enzymes derived 
from intestinal microbiota. Then the thera-
peutic effects can be achieved.
The Chinese microbiologist Zhao (2012) 
adopted a regimen involving Chinese yam 
and bitter melon – fermented prebiotic 
foods – that are believed to change the 
growth of bacteria in the digestive system. 
When he adopted the regimen by comb-
ing these prebiotics with diet composed 
of whole grains, he lost 20 kg in 2 years. 
Furthermore, his blood pressure, heart 
rate, and cholesterol level came down as 
well. The content of Faecalibacterium praus-
nitzii, a bacterium with anti-inflammatory 
properties, increased from an undetectable 
level to 14.5 percentage. of his total gut 
bacteria. The animal experiments showed 
that when rats were given a high fat diet 
(HFD) together with berberine, the major 
pharmacological component of the Chinese 
herb Coptis chinensis or Huanglian, they did 
not develop obesity or insulin resistance. 
What is more, the populations of known 
pathogens decreased while those of known 
beneficial bacteria increased in the gut. 
Other studies in mice also showed that the 
change from a low fat, plant polysaccharide 
diet to a western diet high in sugar, and fat 
would rapidly and profoundly reconfigure 
the composition of microbes in the gut. The 
gut microbiota in response to HFD feeding 
may allow the host to harvest more energy 
from food (Ley et al., 2005; Ley et al., 2006; 
Sanderson et al., 2006).
challenGe and ProsPecT
Though the development of human gut 
microbiome research burst in the last dec-
ade, we are still unenlightened in facing to 
P. gingivalis suggesting that this organism 
plays a role in disease risk and progression 
in RA (Mikuls et al., 2009). Furthermore, 
RA is closely related to periodontal disease. 
In a case-control study, serum antibodies 
against disease-producing periodontal 
bacteria were identified more frequently in 
subjects affected by RA and periodontitis 
than control subjects (Ogrendik et al., 2005; 
Moen et al., 2006).
Commensal gut bacteria are essen-
tial to immune system development, and 
exposures disrupting the infant gut micro-
biota have been considered to be linked to 
asthma. The western diet has been found 
associated with increased risk of asthma for 
children (Nagel et al., 2010), and fast food 
consumption might counteract the pro-
tective effects of prolonged breastfeeding 
(Mai et al., 2009). Following birth, exclu-
sive breastfeeding confers “beneficial” gut 
microbiota to infants, including increased 
colonization by Bifidobacteria and reduced 
prevalence and abundance of C. difficile 
compared to formula-fed infants (Penders 
et al., 2007; Fallani et al., 2010; Roger and 
McCartney, 2010). Infants who are not suf-
ficiently exposed to Bifidobacteria in breast 
milk may have inappropriate immune 
responses to microbial exposures later 
in childhood, leading to atopic disorders 
including asthma. Beside of breast milk 
and other nutritional supplements, anti-
biotics affecting colonization of the intes-
tinal bacteria by suppressing commensal 
bacteria, and causing the emergence of 
asthma-associated pathogens such as C. dif-
ficile are the next most commonly ingested 
substances by infants. The research shows 
that antibiotic use in the immediate period 
after birth can severely alter the composi-
tion and population of gut microbiota in 
infants (Fallani et al., 2010). Additional, the 
perinatal prevention from asthma via the 
intestinal microbiome is a relatively new 
perspective that has evolved long side mod-
ern technologies for the study of microbial 
communities (Azad and Kozyrskyj, 2012).
The Pursue of maniPulaTe The GuT 
microbioTa
The increasingly serious chronic health 
issues, ranging from obesity and diabetes 
to bowel disease and RA, are being demon-
strated to be linked with perturbations in 
gut flora. Hence, it is feasible to treat these 
complex diseases through adjusting the gut 
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therapeutics. Such diagnostics are not yet 
feasible, but given recent advances in our 
ability to survey the human microbiome, 
this possibility is not far in the future, espe-
cially if we are able to identify particular 
components of the human microbiome 
that contribute disproportionately to the 
maintenance of human health. An adaptive 
management approach to clinical medicine 
provides a wonderful example of person-
alized medicine, with treatments tailored 
to individuals on the basis of diagnostic 
changes in an individual’s microbiome, 
and continually adjusted through regular 
monitoring. Such an information-intensive 
approach, guided by ecological theory, has 
the potential to revolutionize the treatment 
of disease.
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